Epilepsy - Pipeline Review, H1 2016

Description: Epilepsy - Pipeline Review, H1 2016

Summary

‘Epilepsy - Pipeline Review, H1 2016’, provides an overview of the Epilepsy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Epilepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Epilepsy
- The report reviews pipeline therapeutics for Epilepsy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Epilepsy therapeutics and enlists all their major and minor projects
- The report assesses Epilepsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Epilepsy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Epilepsy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the
most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

List of Tables
List of Figures
Introduction
Report Coverage
Epilepsy Overview
Therapeutics Development
Pipeline Products for Epilepsy - Overview
Pipeline Products for Epilepsy - Comparative Analysis
Epilepsy - Therapeutics under Development by Companies
Epilepsy - Therapeutics under Investigation by Universities/Institutes
Epilepsy - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Epilepsy - Products under Development by Companies
Epilepsy - Products under Investigation by Universities/Institutes
Epilepsy - Companies Involved in Therapeutics Development

Acorda Therapeutics, Inc.
Adamas Pharmaceuticals, Inc.
Advicenne Pharma
Aeolus Pharmaceuticals, Inc.
Aequus Pharmaceuticals Inc.
Aestus Therapeutics, Inc.
Alexza Pharmaceuticals, Inc.
Anavex Life Sciences Corp.
Aklepios BioPharmaceutical, Inc.
Astellas Pharma Inc.
Bial - Portela & Ca, S.A.
Retrophin Inc.
RODES Inc.
Sage Therapeutics, Inc.
Sanionia AB
SciFluor Life Sciences, LLC
SK Biopharmaceuticals Co., Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
Takeda Pharmaceutical Company Limited
Trillium Therapeutics Inc.
Turing Pharmaceuticals AG
UCB S.A.
Ultragenyx Pharmaceutical Inc.
Upsher-Smith Laboratories, Inc.
Vichem Chemie Research Ltd.
VistaGen Therapeutics, Inc.
Xenon Pharmaceuticals Inc.
XERIS Pharmaceuticals, Inc.
Zogenix, Inc.
Zynerba Pharmaceuticals, Inc.
Epilepsy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
2-DG - Drug Profile
ADS-4101 - Drug Profile
ADV-6208 - Drug Profile
ADV-6770 - Drug Profile
AEOL-1114B - Drug Profile
eslicarbazepine acetate - Drug Profile
everolimus - Drug Profile
fenfluramine hydrochloride - Drug Profile
fosphenytoin sodium - Drug Profile
ganaxolone - Drug Profile
Gene Therapy to Activate Neuropeptide Y Receptor Y2 and Y5 for Epilepsy - Drug Profile
GWP-42006 - Drug Profile
histamine dihydrochloride - Drug Profile
immune globulin (human) - Drug Profile
INV-170 - Drug Profile
IPR-131 - Drug Profile
IPR-96 - Drug Profile
IPRO-003 - Drug Profile
JNJ-40411813 - Drug Profile
KM-113 - Drug Profile
KM-314 - Drug Profile
lacosamide - Drug Profile
lamotrigine - Drug Profile
levetiracetam - Drug Profile
liatermin - Drug Profile
LM22A-4 - Drug Profile
lorazepam - Drug Profile
LSPGR-1 - Drug Profile
LT-4121 - Drug Profile
LT-4122 - Drug Profile
LT-4123 - Drug Profile
LT-4124 - Drug Profile
LT-4125 - Drug Profile
LT-4126 - Drug Profile
magnesium valproate hydrate - Drug Profile
MB-003 - Drug Profile
midazolam hydrochloride - Drug Profile
MP-101 - Drug Profile
MRS-5474 - Drug Profile
naluzotan hydrochloride - Drug Profile
NB-23R1 - Drug Profile
NGT-168 - Drug Profile
NH-34 - Drug Profile
NRP-2945 - Drug Profile
NST-0037 - Drug Profile
NST-0076 - Drug Profile
Oligonucleotide for Dravet Syndrome - Drug Profile
perampanel - Drug Profile
pregabalin - Drug Profile
propofol hemisuccinate - Drug Profile
SAGE-217 - Drug Profile
SAGE-689 - Drug Profile
SCT-66 - Drug Profile
selurampanel - Drug Profile
sepranolone - Drug Profile
SF-0034 - Drug Profile
SGE-872 - Drug Profile
simvastatin - Drug Profile
Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile
Small Molecule 2 for Epilepsy - Drug Profile
Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile
Small Molecule 3 for Epilepsy - Drug Profile
Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile
Small Molecule 4 for Epilepsy - Drug Profile
Small Molecule for Epilepsy - Drug Profile
Small Molecule for Epilepsy - Drug Profile
Small Molecule for Epilepsy - Drug Profile
Small Molecule for Stroke and Epilepsy - Drug Profile
Small Molecule to Activate Kv7.2 and Kv7.3 Channels for Epilepsy and Pain - Drug Profile
Small Molecule to Agonize GABAA Receptor Subunit Alpha-4 and Gamma for Epilepsy - Drug Profile
Small Molecule to Antagonize mGluR5 and mGluR6 for Neurological Disorders - Drug Profile
Small Molecule to Block Nav1.6 for Dravet Syndrome - Drug Profile
Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile
Small Molecules 1 for Epilepsy - Drug Profile
Small Molecules 2 for Epilepsy - Drug Profile
Small Molecules 3 for Epilepsy - Drug Profile
Small Molecules 4 for Epilepsy - Drug Profile
Small Molecules for CNS Disorders - Drug Profile
Small Molecules for Epilepsy - Drug Profile
Small Molecules for Seizures - Drug Profile
Small Molecules to Activate GABAA Receptor and Antagonize NMDA Receptor for CNS - Drug Profile
Small Molecules to Activate Kv7 for Neuropathic Pain, Epilepsy and Tinnitus - Drug Profile
Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile
Small Molecules to Agonize GABA-A Receptor For Epilepsy - Drug Profile
Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Drug Profile
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile
Small Molecules to Inhibit Dynamin for Epilepsy and Oncology - Drug Profile
Small Molecules to Inhibit Voltage Gated Sodium Channels for Lennox Gastaut Syndrome - Drug Profile
sulthiame - Drug Profile
TAK-935 - Drug Profile
TF-0081 - Drug Profile
TG-4155 - Drug Profile
topiramate - Drug Profile
TRP-001 - Drug Profile
TUR-004 - Drug Profile
TUR-005 - Drug Profile
UCB-0942 - Drug Profile
UX-007 - Drug Profile
VAD-1 - Drug Profile
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Comparative Analysis by Unknown Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Products under Development by Companies, H1 2016 (Contd..2)
Products under Development by Companies, H1 2016 (Contd..3)
Products under Development by Companies, H1 2016 (Contd..4)
Products under Development by Companies, H1 2016 (Contd..5)
Products under Development by Companies, H1 2016 (Contd..6)
Products under Development by Companies, H1 2016 (Contd..7)
Products under Development by Companies, H1 2016 (Contd..8)
Products under Investigation by Universities/Institutes, H1 2016
Epilepsy - Pipeline by Acorda Therapeutics, Inc., H1 2016
Epilepsy - Pipeline by Adamas Pharmaceuticals, Inc., H1 2016
Epilepsy - Pipeline by Advicenne Pharma, H1 2016
Epilepsy - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2016
Epilepsy - Pipeline by Aequus Pharmaceuticals Inc., H1 2016
Epilepsy - Pipeline by Aestus Therapeutics, Inc., H1 2016
Epilepsy - Pipeline by Alexza Pharmaceuticals, Inc., H1 2016
Epilepsy - Pipeline by Anavex Life Sciences Corp., H1 2016
Epilepsy - Pipeline by Asklepios BioPharmaceutical, Inc., H1 2016
Epilepsy - Pipeline by Astellas Pharma Inc., H1 2016
Epilepsy - Pipeline by Bial - Portela & Ca, S.A., H1 2016
Epilepsy - Pipeline by BioCrea GmbH, H1 2016
Epilepsy - Pipeline by Biogen, Inc., H1 2016
Epilepsy - Pipeline by Bionomics Limited, H1 2016
Epilepsy - Pipeline by Biovista Inc., H1 2016
Epilepsy - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2016
Epilepsy - Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2016
Epilepsy - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016
Epilepsy - Pipeline by D-Pharm Ltd., H1 2016
Epilepsy - Pipeline by Eisai Co., Ltd., H1 2016
Epilepsy - Pipeline by Grifols, S.A., H1 2016
Epilepsy - Pipeline by GW Pharmaceuticals Plc, H1 2016
Epilepsy - Pipeline by H. Lundbeck A/S, H1 2016
Epilepsy - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2016
Epilepsy - Pipeline by INSYS Therapeutics, Inc., H1 2016
Epilepsy - Pipeline by INVENT Pharmaceuticals, Inc., H1 2016
Epilepsy - Pipeline by Iproteos S.L., H1 2016
Epilepsy - Pipeline by Johnson & Johnson, H1 2016
Epilepsy - Pipeline by Knopp Biosciences LLC, H1 2016
Epilepsy - Pipeline by Lipicard Technologies Limited, H1 2016
Epilepsy - Pipeline by Marathon Pharmaceuticals, LLC, H1 2016
Epilepsy - Pipeline by Marinus Pharmaceuticals, Inc., H1 2016
Epilepsy - Pipeline by MedGenesis Therapeutix Inc., H1 2016
Epilepsy - Pipeline by Nemus Bioscience, Inc., H1 2016
Epilepsy - Pipeline by Neurelis, Inc., H1 2016
Epilepsy - Pipeline by Neurocrine Biosciences, Inc., H1 2016
Epilepsy - Pipeline by Neuron Biopharma SA, H1 2016
Epilepsy - Pipeline by Novartis AG, H1 2016
Epilepsy - Pipeline by OPKO Health, Inc., H1 2016
Epilepsy - Pipeline by Pfizer Inc., H1 2016
Epilepsy - Pipeline by PharmatrophiX, Inc., H1 2016
Epilepsy - Pipeline by Promius Pharma, LLC, H1 2016
Epilepsy - Pipeline by PTC Therapeutics, Inc., H1 2016
Epilepsy - Pipeline by Retrophin Inc., H1 2016
Epilepsy - Pipeline by RODES Inc., H1 2016
Epilepsy - Pipeline by Sage Therapeutics, Inc., H1 2016
Epilepsy - Pipeline by Saniona AB, H1 2016
Epilepsy - Pipeline by SciFluor Life Sciences, LLC, H1 2016
Epilepsy - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016
Epilepsy - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Top 10 Routes of Administration, H1 2016
Number of Products by Stage and Top 10 Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/3674292/](http://www.researchandmarkets.com/reports/3674292/)
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- Product Name: Epilepsy - Pipeline Review, H1 2016
- Web Address: http://www.researchandmarkets.com/reports/3674292/
- Office Code: SCH3X2DB

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td></td>
<td>USD 2000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td>USD 4000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Site License:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td>USD 6000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr | Mrs | Dr | Miss | Ms | Prof

First Name: ___________________________ Last Name: ___________________________

Email Address: * ___________________________

Job Title: ___________________________

Organisation: ___________________________

Address: ___________________________

City: ___________________________

Postal / Zip Code: ___________________________

Country: ___________________________

Phone Number: ___________________________

Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World